Hybrigenics Presents Data on Investigational Anti-Cancer Agent That May Need Companion Test

The data, while preliminary, suggests that the drug might require a companion diagnostic to establish p53 status prior to treatment, company officials said.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.